ADDRESS-2 is supporting a study to assess the safety of a new “type 1 diabetes vaccine” designed to stop the immune system from attacking insulin-producing beta cells.
ADDRESS-2 is supporting a study to assess the safety of a new “type 1 diabetes vaccine” designed to stop the immune system from attacking insulin-producing beta cells.